FDA recommends that the Drug Enforcement Administration down-classify marijuana from Schedule 1 to Schedule 3 under the Controlled Substances Act.
FDA grants Nurix Therapeutics a fast track designation for NX-5948 for treating certain adult patients with relapsed or refractory chronic lymphocytic...
Federal Register notice: FDA revises an information collection entitled Premarket Notification for a New Dietary Ingredient (NDI) 21 CFR 190.6.
FDA warns San Diego, CA-based Dr. Joel Kaplan Inc. about multiple violations in its manufacturing and distribution of several devices intended to enha...
A physician survey conducted by UCSF researchers finds many doctors dont understand how FDA approves new drugs and medical devices.
Hemogenyx Pharmaceuticals files its complete response to an FDA HEMO-CAR-T clinical hold in hopes of starting Phase 1 trials.
FDA publishes the summary of an October 2023 public meeting on continuing the Covid-19 lessons learned for modernization and innovation in clinical tr...
A month after gaining FDA approval for treating sickle cell disease with the gene therapy Casgevy, Vertex secures its second approval for treating tra...
